Feb. 20, 2025

Confirmation of Phase 2-readiness of AKR101-documentation for a clinical study in chronic wound patients.
The Federal Institute for Drugs and Medical Devices in Germany, BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte), confirms in a scientific advice meeting that the documentation of AKR101 is ready for a Phase 2 clinical study in chronic wound patients.